5264-35-7,With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.5264-35-7,5-Methoxy-3,4-dihydro-2H-pyrrole,as a common compound, the synthetic route is as follows.
Ethyl 7-hydroxy-6-methyl-5-oxo-1,2,3,5-tetrahydroindolizine-8-carboxylate (8b) Compound 8a (Aust. J. Chem., 1999, 52, 1013-1020, 7 g, 32.3 mmol) was added to a mixture of triethylamine (0.16 mL, 1.15 mmol) and 2-methoxy-1-pyrroline (2.9 g, 29.4 mmol) and the reaction was stirred at room temperature for 10 days. The solution was concentrated in vacuo and the resulting solid was filtered and washed with diethyl ether to give 1.83 g (22percent) of the title compound as a white solid powder. 1H NMR (400 MHz,DMSO-d6): delta 11.47 (s, 1H), 4.33 (q, 2H, J=7.1 Hz), 4.00 (t, 1H, J=7.6 Hz), 3.44 (t, 2H, J=8.0 Hz), 2.03-2.16 (m, 2H), 1.83 (s, 3H), 1.33 (t, 3H, J=7.1 Hz). MS (ES) [m+H] calc’d for C12H15NO4, 238; found 238.
The synthetic route of 5264-35-7 has been constantly updated, and we look forward to future research findings.
Reference£º
Patent; TAKEDA PHARMACEUTICAL COMPANY LIMITED; US2009/124595; (2009); A1;,
Pyrroline – Wikipedia
1-Pyrroline | C4H7N – PubChem